Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CSF1R F563_P566del |
| Therapy | Pexidartinib |
| Indication/Tumor Type | Erdheim-Chester disease |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CSF1R F563_P566del | Erdheim-Chester disease | predicted - resistant | Pexidartinib | Case Reports/Case Series | Actionable | In a clinical case study, CSF1R F563_P566del was identified at the time of progression, along with loss of the original CSF1R S560_P566del and S938_Y969del mutations, in a patient with Erheim-Chester disease, who originally achieved a partial response with Turalio (pexidartinib) treatment (PMID: 39576953). | 39576953 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39576953) | Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations. | Full reference... |